Beauty Health delivered a strong performance in Q2 2025, exceeding revenue and Adjusted EBITDA expectations. The company reported net sales of $78.2 million and a net income of $19.7 million, a significant increase from the prior year. This was primarily driven by strong consumables sales and improved gross margins, despite a decrease in delivery systems sales.

BeautyHealth reported first quarter 2025 results with net sales of $69.6 million, a decrease of 14.5% year-over-year, primarily due to lower delivery system sales. Despite the revenue decline, the company improved its gross margin and adjusted EBITDA, driven by cost efficiencies and a favorable shift towards consumables revenue.

BeautyHealth's Q4 2024 revenue was $83.5 million, a 13.8% decrease year-over-year, driven by lower delivery system sales. The company improved its gross margin to 62.7% and adjusted EBITDA reached $9.0 million. Consumable sales grew, and cost-cutting efforts helped offset revenue declines.

BeautyHealth reported Q3 2024 net sales of $78.8 million, a decrease of 19.1% compared to Q3 2023. However, the company saw improved profitability with an increase in gross margin and adjusted EBITDA, driven by operational excellence initiatives and disciplined expense management. The company also revised its full year net sales guidance lower and improved its adjusted EBITDA guidance.

BeautyHealth's Q2 2024 results showed net sales of $90.6 million, a decrease of (22.9)% compared to the same period in 2023. This was due to lower equipment sales, partially offset by growth in consumables net sales. The company is addressing these challenges by offering lower-priced device options and additional financing solutions to providers.

BeautyHealth's first quarter net sales reached $81.4 million, a decrease of (5.7)% compared to the same period in 2023, with lower equipment sales offset by growth in consumables. The company reported a net loss of $(0.7) million, an improvement from the prior year, and an adjusted EBITDA of $0.4 million.

BeautyHealth reported Q4 2023 financial results with net sales of $96.8 million, a decrease of (1.3)% compared to the prior year period. The results reflect lower equipment sales in the Americas, substantially offset by steady growth in Americas consumables net sales and strong device placement in Asia-Pacific.

Beauty Health's Q3 2023 net sales increased by 10% year-over-year to $97.4 million, driven by growth in APAC and EMEA. However, lower-than-expected U.S. revenue and $63.1 million in restructuring charges related to device upgrades impacted the quarter. The company is revising its fiscal year 2023 net sales guidance to $385 to $400 million and adjusted EBITDA margin guidance to 5% to 6%, and suspending its long-term 2025 financial outlook.

BeautyHealth reported a 13% year-over-year increase in net sales, reaching $117.5 million. Net income was $3.4 million, and the adjusted EBITDA margin was 15.1%. The company reaffirmed its 2023 net sales and long-term 2025 financial guidance, and refined its 2023 adjusted EBITDA margin to a more precise 18%-19% range.

BeautyHealth reported a 14% increase in net sales to $86.3 million, driven by strong consumer demand for Hydrafacial treatments. The company raised its fiscal year 2023 net sales guidance to $460 - $480 million and reaffirmed its adjusted EBITDA margin guidance of 18% - 20%.

BeautyHealth reported a strong Q4 2022, with net sales increasing by 26% year-over-year to $98.1 million and net income reaching $3.8 million. Adjusted EBITDA also saw a substantial increase of 92% to $16.3 million. The company's performance was driven by growth in both delivery systems and consumables, with notable contributions from the Americas and APAC regions.

BeautyHealth reported strong Q3 2022 financial results, with net sales of $88.8 million, representing a 30% year-over-year growth. The company raised its full year net sales guidance to $360 million to $365 million. Adjusted EBITDA for the quarter was $16.5 million, with a GAAP net income of $0.1 million. However, due to increasing macro pressures, the company revised its full year 2022 adjusted EBITDA guidance to a range of $45.0 to $50.0 million.

BeautyHealth announced record second-quarter results with net sales growth of 55.7% year-over-year, reaching $103.5 million. The company raised its full-year net sales guidance and reaffirmed its adjusted EBITDA outlook, driven by strong demand for HydraFacial delivery systems and healthy consumer interest.

BeautyHealth reported a strong first quarter with net sales increasing by 58.6% to $75.4 million. The company raised its full-year net sales guidance to $330-340 million, reflecting confidence in its growth plan.

The Beauty Health Company reported strong Q4 2021 results with net sales increasing 105.6% compared to Q4 2020, driven by growth in the U.S., EMEA, and APAC regions. The company exceeded its guidance for the quarter and full year, navigating macro challenges and COVID-19 impacts.

The Beauty Health Company reported a strong third quarter with net sales of $68.1 million, a 97% increase compared to Q3 2020. The company raised its full-year guidance for net sales to $245 million to $255 million and adjusted EBITDA to $30 million.

The Beauty Health Company reported exceptional second-quarter results with a 371.2% increase in net sales compared to Q2 2020, driven by strong performance in both Delivery Systems and Consumables. The company is raising its full-year sales guidance to $230 million to $240 million.

The Beauty Health Company reported a strong first quarter with net sales of $47.5 million, a 46% increase year-over-year. The company's performance was driven by strong sales in both delivery systems and consumables, and they have updated their top-line guidance for 2021 to approximately $200 million.